Showing 15 posts of 74 posts found.


FDA approves Janssen’s Xarelto for blood clot prevention

October 15, 2019
Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism

Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …

Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease

August 1, 2019
Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma

NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …


J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far

January 11, 2019
Medical Communications, Sales and Marketing J&J, JJ, Stelara, US, Xarelto, Zytiga, pharma, price hikes

It’s only the second week of the New Year, and Johnson & Johnson has announced plans to hike the prices …


Bayer and J&J successfully reverse $28 million Xarelto court payout

January 10, 2018
Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …


Bayer forced to halt huge study into key drug

October 6, 2017
Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical

Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …

Bayer’s cardiovascular drug races to target in trial

February 9, 2017
Research and Development, Sales and Marketing Bayer, Janssen, Xarelto

Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …


Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …


Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …


Bayer backs safety of Xarelto after real-world data study

September 2, 2015
Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …

Xarelto image

Bayer promotes Xarelto benefits

June 15, 2015
Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban

Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …


Chinese government to lift drug price controls

May 5, 2015
Sales and Marketing China, Drug pricing, GSK, IMS, Xarelto, government

The Chinese government has announced that it will remove price caps for most medicines and allow the market to play …


Bayer buys blood-thinning drug from Isis

May 5, 2015
Research and Development, Sales and Marketing Bayer, Eliquis, ISIS-FXI, Isis, Xarelto, blooding thinning

German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …

Bayer image

Profits fall at Bayer but new drugs see growth

May 1, 2015
Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban

Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …

Latest content